uniQure Targets Q3 2026 BLA Submission for Huntington’s Gene Therapy
Event summary
- uniQure plans to submit a Biologics License Application (BLA) for AMT-130 in Huntington’s disease by Q3 2026, following FDA agreement that 3-year Phase I/II data can support accelerated approval.
- FDA proposed aligning on a confirmatory study design with a concurrent control on standard-of-care therapy instead of a sham procedure.
- AMT-130 has received RMAT, Breakthrough Therapy, and Fast Track designations from the FDA.
- Phase I/II studies involved 26 patients in the U.S. and 13 in Europe, with additional cohorts exploring dose escalation and immunosuppression.
The big picture
uniQure’s push for accelerated approval of AMT-130 reflects the growing momentum in gene therapy for neurodegenerative diseases, where regulatory pathways are increasingly streamlined for treatments addressing severe unmet needs. The FDA’s willingness to consider alternative study designs underscores the agency’s commitment to expediting therapies for conditions like Huntington’s disease, which currently lack approved treatments to slow progression.
What we're watching
- Regulatory Alignment
- Whether uniQure and the FDA can finalize the confirmatory study design before BLA submission, particularly the shift to a standard-of-care control arm.
- Clinical Efficacy
- The strength of the 3-year Phase I/II data in supporting accelerated approval and its potential impact on long-term patient outcomes.
- Market Timing
- The pace at which uniQure can advance AMT-130 through regulatory hurdles and bring it to market, given the unmet need in Huntington’s disease.
Related topics